2:07-mc-00219 | D. Kan. | Aug 30, 2007
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 1 of 26
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF KANSAS
MERIAL LIMITED and MERIAL )
SAS, )
)
Movants, )
)
v. ) D. Kan. Case No. 07-MC-219-CM
)
DR. RAYMOND R.R. ROWLAND, ) (Related to Case No. 1:06-CV-658
) in the U.S. District Court for the
) District of Columbia)
Objector. )
MEMORANDUM AND ORDER
I. Introduction
On August 23, 2007, pursuant to Fed. R. Civ. P. 45(c)(2)(B) & (c)(3)(A), the
undersigned U.S. Magistrate Judge, James P. O’Hara, conducted a hearing on a motion to
compel filed by Merial Limited and its French affiliate, Merial SAS (collectively, “Merial”)
(doc. 1). This motion seeks to compel the production of certain documents subpoened from
Raymond R.R. Rowland (“Dr. Rowland”), an expert witness retained by Intervet, Inc.
(“Intervet”) in a patent case in the United States District Court for the District of Columbia
(the “D.C. Action”). In addition, Merial seeks to require Dr. Rowland to appear for a second
deposition once he has produced all the requested documents. Merial and Dr. Rowland (the
latter being represented by the same attorneys as Intervet), filed lengthy memoranda and
exhibits before the hearing (see docs. 7, 30, 36-39, & 42-43); with leave of court, counsel for
O:\ORDERS\07-219-CM-1.wpd
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 2 of 26
Intervet and Dr. Rowland filed a supplemental declaration on August 27, 2007, limited to one
narrow issue (see doc. 49).
Merial appeared at the hearing through its counsel, Thomas J. Kowalski, J. Patrick
Elsevier, and D.A.N. Chase. Dr. Rowland appeared though his counsel, Jerry Canada and
Samuel P. Logan; also present was Anne Li (although not of record in this case, Ms. Li
practices with Mr. Canada’s firm).
This order will serve to memorialize the court’s ruling and the rationale for same. As
explained below, Merial’s motion will be granted in part and denied in part.
II. Background
Merial is a joint venture of two large pharmaceutical businesses, Merck and Sanofi-
Aventis. It develops, produces, and sells veterinary pharmaceuticals and vaccines for
livestock, pets, and wildlife. The patent at issue here involves a pig vaccine.
On December 15, 2005, Merial Limited filed suit against Intervet in the United States
District Court for the Northern District of Georgia (the “Georgia Action”), alleging that
Intervet’s sales of a vaccine intended for swine infringed U.S. Patent No. 6,368,601 (the
“‘601 patent”). Intervet moved to dismiss, asserting that Merial Limited was not an owner
of the ‘601 patent and therefore did not have standing to bring suit. On April 27, 2006, the
Northern District of Georgia dismissed the Georgia Action, without prejudice, as improperly
brought.1 Prior to the dismissal of the Georgia Action, Intervet filed a separate declaratory
1
Merial Ltd. v. Intervet, Inc., 430 F. Supp. 2d 1357" date_filed="2006-04-27" court="N.D. Ga." case_name="Merial Ltd. v. Intervet Inc.">430 F. Supp. 2d 1357, 1364 (N.D. Ga. 2006).
O:\ORDERS\07-219-CM-1.wpd -2-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 3 of 26
judgment action against Merial, i.e., the D.C. Action.2
On July 11, 2006, after the initiation of the D.C. Action, Intervet retained Dr. Rowland
to assist in construing the claims of the ‘601 patent. Dr. Rowland is a professor and research
scientist in the College of Veterinary Medicine at Kansas State University (“K-State”) in
Manhattan, Kansas. He specializes in swine health matters.
Dr. Rowland has worked actively with Intervet’s counsel to develop Intervet’s claim
construction positions. As part of this effort, Dr. Rowland has traveled from Kansas to
Washington, D.C. to meet with Intervet’s outside counsel and has engaged in telephone calls
with them regarding claim construction.
On Wednesday, May 2, 2007, Intervet filed its opening brief in connection with the
anticipated Markman hearing in the D.C. Action.3 As part of that submission, Intervet
included a written declaration by Dr. Rowland (the “Rowland Declaration”) which included
the expert witness disclosures required under Fed. R. Civ. P. 26(a)(2). Prior to the
submission of claim construction briefs and the exchange of expert declarations, Intervet and
Merial had agreed that their respective claim construction experts, such as Dr. Rowland,
would be deposed during the period between opening and answering claim construction
briefs.
2
Case No. 06-CV-00658 in the U.S. District Court for the District of Columbia.
3
See Markman v. Westview Instruments, Inc., 52 F.3d 967" date_filed="1995-04-05" court="Fed. Cir." case_name="Herbert Markman and Positek, Inc. v. Westview Instruments, Inc. And Althon Enterprises, Inc.">52 F.3d 967, 976, 980 (Fed. Cir. 1995).
O:\ORDERS\07-219-CM-1.wpd -3-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 4 of 26
On Friday, May 4, 2007, Merial served a subpoena on Dr. Rowland.4 The subpoena
4
For the benefit of context, the court notes that this subpoena, in its entirety, states as
follows:
You are requested to produce for inspection and copying as set forth in the
attached subpoena the documents listed below:
1. All non-identical drafts of your Declaration, including,
but not limited to, all handwritten or typed drafts of your
Declaration, and including any outlines of your Declaration and
any notes related to your Declaration prepared or taken in
advance of or during the preparation of your Declaration.
2. All documents, data, communications or other
information you generated, reviewed or considered in generating
or preparing your Declaration or informing the opinions
expressed in your Declaration.
3. All annotated copies of any documents and things
responsive to Request No.2 above.
4. All documents reflecting, referring, or relating to any
communications with others regarding or relating to any of (1)
the subject matter of your Declaration; (2) any of the opinions
expressed in your Declaration; (3) the ‘601 patent; (4) the
Intervet v. Merial litigation; (5) the Merial v. Intervet litigation,
(6) the Intervet PCV-2 vaccine; and/or (7) the ‘594 patent,
including, but not limited to, any such communications with
Intervet, Kenyon, or any experts or consultants for Intervet or
Kenyon, including, but not limited to, Dr. Fernando A. Osorio,
M.V., Ph.D.
4. All documents that were provided to you by either
Intervet, Kenyon, or any experts or consultants for Intervet or
Kenyon, including, but not limited to, Dr. Fernando A. Osorio,
M.V., Ph.D., that reflect, refer, or relate to any of (l) the subject
matter of your Declaration; (2) any opinions expressed in your
Declaration, (3) the ‘601 patent; (4) the Intervet v. Merial
litigation; (5) the Merial v. Intervet litigation, (6) the Intervet
O:\ORDERS\07-219-CM-1.wpd -4-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 5 of 26
commanded the production of various documents5 by the following Wednesday (May 9,
2007) at 9:00 a.m., and also required Dr. Rowland to appear for a deposition on May 16,
2007.
On May 9, 2007, in response to the subpoena, Dr. Rowland produced approximately
PCV-2 vaccine; and/or (7) the ‘594 patent.
5. All articles, letters, papers, or abstracts, presentations,
publications, authored, co-authored, published, submitted for
publication, or given by you relating to the subject matter of
your Declaration, including, but not limited to, any such articles,
letters, or papers relating to PCV, PCV-1, PCV-2, vectors, Open
Reading Frames (ORFs), or epitopes,
6. All documents that reflect, refer, or relate to any payment
or compensation, or expected payment or compensation, for
your services in the lntervet v. Merial litigation, including, but
not limited to, any retainer or engagement agreements.
7. All documents that reflect, refer, or relate to any
payments to you or your employer by Intervet relating to any
research, tests, trials, or experiments relating to the Intervet
PCV-2 vaccine.
8. All documents that reflect, refer, or relate to the ‘601
patent, the application that resulted in the ‘601 patent, and/or
any patent application to which the ‘601 patent claims priority,
including, but not limited to, all documents that reflect, refer, or
relate to any infringement or alleged infringement, scope,
validity, or enforceability of the ‘601 patent.
9. All documents that reflect, refer or relate to any cases for
which you have been retained as an expert witness, including
but not limited to all reports, deposition transcripts, trial
transcripts, and engagement agreements.
5
The court notes that the subpoena actually seeks 10 categories of documents, but due
to misnumbering, reflects only 9 categories.
O:\ORDERS\07-219-CM-1.wpd -5-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 6 of 26
1,300 pages of documents. He also served written objections to Merial’s requests for
production. On May 16, 2007, Dr. Rowland was deposed. On June 11, 2007, asserting that
Dr. Rowland had failed to produce certain requested items, Merial filed the instant motion
in this court.
As earlier indicated, Merial now seeks an order compelling Dr. Rowland to provide
materials in what Merial deems to be full and complete compliance with the subpoena, and
to require Dr. Rowland to appear for further deposition testimony after he has provided all
of those materials. The thrust of Merial’s motion, at least when it was filed, was that the
requested discovery from Dr. Rowland was necessary to prepare for the Markman hearing
in the D.C. Action; according to Merial, however, Dr. Rowland’s testimony is relevant not
only for Markman purposes but also Merial’s contention that Intervet has infringed and
continues to infringe the ‘601 patent.
The Markman hearing originally was scheduled for June 21, 2007, and later was
continued to August 6, 2007. The Hon. Henry H. Kennedy, Jr., the presiding U.S. District
Judge in the D.C. Action, conducted the Markman hearing on August 6 and 7, 2007. During
the August 23, 2007 hearing in this court, it was disclosed that the Markman hearing had
proceeded without any significant objection by Merial based on the unresolved motion to
compel in this court involving Dr. Rowland. In any event, the parties expect Judge Kennedy
to issue his Markman claim construction ruling sometime prior to a status conference that he
has scheduled for October 5, 2007.
Evidently, November 16, 2007 is the fact discovery cutoff date in the D.C. Action.
O:\ORDERS\07-219-CM-1.wpd -6-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 7 of 26
Expert discovery in the D.C. Action is slated to begin December 17, 2007 and end on March
7, 2008.
III. Analysis & Discussion
Merial contends that Dr. Rowland failed to diligently search for and produce all of the
documents technically covered by the subpoena. This is a scenario which, in the
undersigned’s nearly thirty years experience as a trial lawyer and a judge, is not all that
uncommon. Despite dealing with a fairly typical problem, the written submissions by Merial
and Dr. Rowland in this matter unfortunately are cluttered by numerous digressions on minor
or immaterial points. The problem is compounded by accusations about “schemes,”
spoilation of evidence, and otherwise sanctionable conduct. Even in high-stakes litigation,
and even taking into account the entirely appropriate call for zealous advocacy, the pleadings
filed in this case frankly are a bit beyond the pale. Merial has submitted the requisite
certificate pursuant to D. Kan. Rule 37.2 that counsel conferred in a good faith attempt to
resolve their dispute before Merial filed the instant motion. Still, the court is inclined to
believe that had the parties and counsel spent half the time and fees consumed by the briefing
process working toward practical compromises, on their worst day they could have arrived
at a better solution than the court can hope to on its best. The parties’ written submissions
here, particularly given the patent at issue, bring to mind the Seventh Circuit’s oft-quoted
bromide that “[j]udges are not like pigs, hunting for truffles buried in briefs.”6 In any event,
the court will endeavor to slog through the record and rule as best it can.
6
United States v. Dunkel, 927 F.2d 955" date_filed="1991-03-08" court="7th Cir." case_name="United States v. James C. Dunkel">927 F.2d 955, 956 (7th Cir.1991) (emphasis added).
O:\ORDERS\07-219-CM-1.wpd -7-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 8 of 26
Based on the record presented about the underlying circumstances involved, the court
does not hesitate in finding that Dr. Rowland made reasonable, albeit imperfect, efforts to
produce documents in response to Merial’s subpoena. This order will explain what
additional documents Dr. Rowland will have to retrieve and produce, at which time he will
sit for additional deposition testimony.
Dr. Rowland and Intervet argue that the issues raised in Merial’s motion are moot or
at least are not terribly pressing in light of the fact that the Markman hearing already has
been conducted by Judge Kennedy in the D.C. Action. Merial argues that, while a Markman
ruling is anticipated within the month, there is no ruling yet. Merial also argues that the
Markman record remains open. In this regard, Merial cites Jack Guttman, Inc. v. Kopykake
Enterprises, Inc.,7 and Honeywell International, Inc. v. United States,8 for the proposition that
claim construction is a “rolling” process and that claim constructions are revisited or altered
as the record is developed. Merial also argues that the requested information will be used
to develop the record in the event of any appeal.
A. Document Request Issues
A bit narrower than what purportedly is called for by the subpoena, the specific
documents sought by Merial’s motion appear to be as follows:
7
302 F.3d 1352" date_filed="2002-08-30" court="Fed. Cir." case_name="Jack Guttman, Inc. v. Kopykake Enterprises, Inc.">302 F.3d 1352, 1361 (Fed. Cir. 2002).
8
70 Fed. Cl. 424" date_filed="2006-04-28" court="Fed. Cl." case_name="Honeywell International, Inc. v. United States">70 Fed. Cl. 424, 447-48 (Fed. Cl. 2006).
O:\ORDERS\07-219-CM-1.wpd -8-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 9 of 26
1) An unpublished paper on PCV-2 and all drafts thereof, and drafts of a
published paper on PCV-2.9 As to the unpublished paper on PCV-2, Dr. Rowland asserts
in his responsive brief (doc. 30 at 11), and at the hearing, that a version (presumably the final
version) of this paper has been produced to Merial by K-State in response to a separate
subpoena that was served on the university on or about May 21, 2007.10 But Merial now says
9
As earlier indicated, Request No. 5 in the subpoena that Merial served on Dr.
Rowland seeks “[a]ll articles, letters, papers, or abstracts, presentations, publications,
authored, co-authored, published, submitted for publication, or given by you relating to the
subject matter of your Declaration, including, but not limited to, any such articles, letters, or
papers relating to PCV, PCV-1, PCV-2, vectors, Open Reading Frames (ORFs), or epitopes.”
10
Here again, for the benefit of context, the court will set forth all of the document
requests in Merial’s K-State subpoena. They are as follows:
You are requested to produce for inspection and copying as set forth in
the attached subpoena the documents listed below:
Request No. 1.
Each document or thing concerning any communication,
understanding, license, or agreement between Kansas State
University and Intervet relating to any porcine circovirus
diagnostic or vaccine.
Request No. 2.
Each document or thing concerning Invervet’s Porcine
Circovirus Vaccine, Type 2, Killed Baculovirus Vector.
Request No. 3.
Each document or thing concerning the conception,
research, development, testing, regulatory approval,
manufacture, production, marketing, sale, or use of Intervet’s
Porcine Circovirus Vaccine, Type 2, Killed Baculovirus Vector.
Request No. 4.
Any report, summary, compilation, or abstract
concerning sales of or royalties from Intervet’s Procine
O:\ORDERS\07-219-CM-1.wpd -9-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 10 of 26
Circovirus Vaccine, Type 2, Killed Baculovirus Vector.
Request No. 5.
Each document or thing concerning a royalty based On
Intervet’s Porcine Circovirus Vaccine, Type 2, Killed
Baculovirus Vector.
Request No. 6.
Each document or thing concerning a license or
agreement under which Kansas State University granted any
rights relating to a porcine circovirus diagnostic or vaccine,
including but not limited to any royalties received or any other
economic consideration obtained by Kansas State University.
Request No. 7.
Each document or thing concerning a license or
agreement under which Kansas State University received any
rights relating to a porcine circovirus diagnostic or vaccine,
including but not limited to any royalties paid or any other
economic consideration provided by Kansas State University.
Request No. 8.
Each document or thing concerning any payment or other
compensation received by an employee or agent of Kansas State
University based on sales of a porcine circovirus diagnostic PI
vaccine, including but not limited to any payment or other
compensation furnished to Dr. Raymond Rowland or Dr.
Richard Hesse.
Request No. 9.
Each document or thing concerning a patent application
pertaining to a porcine circovirus diagnostic or vaccine.
Request No. 10.
Each document or thing concerning a patent application
relating to a diagnostic or vaccine described in KSURF
Technology Licensing Profile Ref. No. 06-41, including but not
limited to patent applications, and drafts thereof, directed to
diagnostics or vaccines associated with PCV2-321 or PCV2-422
(or both).
O:\ORDERS\07-219-CM-1.wpd -10-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 11 of 26
Request No. 11.
Each document or thing concerning the funding for the
research resulting in a diagnostic or vaccine described in
KSURF Technology License Profile Ref. No. 06-41, including
but not limited to diagnostics or vaccines associated with PCV2-
321 or PCV2-422 (or both).
Request No. 12.
Each document or thing concerning a transfer, grant,
conveyance, assignment, or license of any interest in or right
under any patent or patent application pertaining to a porcine
circovirus vaccine.
Request No. 13.
Each document or thing concerning an analysis,
investigation, inspection, examination, measurement, or test of
any DNA molecule isolated from a porcine circovirus
(e.g.,Porcine Circovirus Type 2).
Request No. 14.
Each document or thing concerning an analysis,
investigation, inspection, examination, measurement, or test of
any porcine circovirus vaccine.
Request No. 15.
Each document or thing concerning any contacts or
communications between(a) Kansas State University or anyone
on Kansas State University’s behalf and(b) Intervet or anyone
on Intervet’s behalf, including but not limited to Intervet’s
attorneys, (e.g., Kenyon and Kenyon, LLP).
Request No. 16.
Each document or thing concerning the isolations of a
porcine circovirus (e.g., Porcine Circovirus Type 2), including
but not limited to research notebooks, laboratory notebooks,
correspondence, invention disclosures, analyses, studies,
experiments, reports, sketches, interview reports or summaries,
descriptions of tests or studies, and results or conclusions
reached from such tests or studies.
O:\ORDERS\07-219-CM-1.wpd -11-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 12 of 26
it requires all versions of this paper, specifically, including but not limited to, drafts showing
Dr. Rowland’s annotations.
Request No. 17.
Each document or thing concerning the isolation of a
DNA molecule from a porcine circovirus (e.g., Porcine
Circovirus Type 2), including but not limited to research
notebooks, laboratory notebooks, correspondence, invention
disclosures, analyses, studies, experiments, reports, sketches,
interview reports or summaries, descriptions of tests or studies,
and results or conclusions reached from such tests or studies.
Request No. 18.
Each document or thing concerning the conception,
research, development. testing, regulatory approval,
manufacture, production, marketing, sale, or use of a diagnostic
or vaccine based on a provine circovirus (e.g., a diagnostic or
vaccine based on Porcine Circovirus Type 2), including but not
limited to research notebooks, laboratory notebooks,
correspondence, invention disclosures, analyses, studies,
experiments, reports, sketches, interview reports or summaries,
clinical data, descriptions of tests or studies, and results or
conclusions reached from such tests or studies.
Request No. 19.
Each document or thing concerning Dr. Raymond
Rowland’s work as an expert or consultant for Kenyon &
Kenyon LLP or Intervet in the Intervet v. Merial litigation.
Request No. 20.
Each document or thing concerning any patent
application or patent in whole or in part assigned to or owned by
Merial concerning porcine circovirus, including but not limited
to the ‘601 patent.
The court has reviewed the subpoena that Merial served on K-State and finds each of
the 20 requests incredibly broad in scope. Merial should consider itself fortunate that K-
State produced anything instead of just objecting.
O:\ORDERS\07-219-CM-1.wpd -12-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 13 of 26
As to the published paper, in its motion, Merial states that it has obtained a copy of
the paper independently. However, at the hearing, Merial requested drafts of the published
paper.
The court finds that Request No. 5, even when construed with the general instructions
and definitions which proceed the requests, does not seek drafts of any of the requested
documents, which includes the published and unpublished papers at issue. The court is
unpersuaded that Merial is entitled to this material. Therefore, this part of the motion is
denied.
2) An abstract from a scientific meeting Dr. Rowland authored on PCV-2.11
Dr. Rowland argues that this document is publicly available and that, in his written
objections to the subject subpoena, “made clear that he would not be producing publicly
available materials.” Of course, the law is well-settled that the mere fact that a document
might be available through another means (i.e., “publicly available” or otherwise) does not
relieve a person of his obligation to produce a document pursuant to the subpoena.12
11
This also is the subject of Request No. 5 in the subpoena that Merial served on Dr.
Rowland (see footnote 4 above).
12
See Am. Maplan Corp. v. Heilmayr, No. 00-2512, 2001 WL 1718366, at *2 (D.
Kan. July 27, 2001). See also St. Paul Reinsurance Co., Ltd. v. Commercial Fin. Corp., 198
F.R.D. 508, 514 (N.D. Iowa 2000) (citing City Consumer Servs. v. Horne, 100 F.R.D. 740" date_filed="1983-12-21" court="D. Utah" case_name="City Consumer Services, Inc. v. David G.">100 F.R.D. 740,
747 (D. Utah 1983) (stating that it is “not usually a ground for objection that the information
is equally available to the interrogator or is a matter of public record”) (citing Petruska v.
Johns-Manville, 83 F.R.D. 32" date_filed="1979-04-30" court="E.D. Pa." case_name="Petruska v. Johns-Manville">83 F.R.D. 32, 35 (E.D. Pa.1979)); Associated Wholesale Grocers, Inc. v.
United States, No. 86-2261, 1989 WL 110300, at *3 (D. Kan. June 7, 1989) (stating that
defendant’s argument of equal accessibility is not sufficient to resist discovery) (citing City
Consumer Services)).
O:\ORDERS\07-219-CM-1.wpd -13-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 14 of 26
Therefore, Dr. Rowland’s specious objection is overruled. He shall produce the requested
document. In this respect, Merial’s motion is granted.
3) Copy of Dr. Rowland’s patent application relating to PCV-2.13 Dr.
Rowland asserts in his responsive brief (doc. 30 at 11) that a version (presumably the final
version) of this paper already has been produced to Merial by K-State in response to a
separate subpoena. Merial understandably wants all versions of the application. The court
agrees that Merial is entitled to this material. Therefore, this part of the motion is granted.
4) Documents relating to Dr. Rowland’s prior expert consultancy.14 Dr.
Rowland asserts that the materials related to his prior expert consultancy relate to a case ten
years ago between companies that are not parties to this suit and regarding a virus that is not
claimed in Merial’s patent. In this regard, Dr. Rowland largely relies on Fed. R. Civ. P.
26(a)(2)(B), which requires an expert to disclose “a listing of any other cases in which the
witness has testified as an expert at trial or by deposition within the preceding four years”
(emphasis added). Dr. Rowland argues that these materials are outside of the bounds of
discovery contemplated by Rule 26(a)(2) and that Merial should not be allowed to use its
13
Request No. 8 in the subpoena served on Dr. Rowland seeks “[a]ll documents that
reflect, refer, or relate to the ‘601 patent, the application that resulted in the ‘601 patent,
and/or any patent application to which the ‘601 patent claims priority, including, but not
limited to, all documents that reflect, refer, or relate to any infringement or alleged
infringement, scope, validity, or enforceability of the ‘601 patent.”
14
Request No. 9 in the subpoena served on Dr. Rowland seeks “[a]ll documents that
reflect, refer or relate to any cases for which you have been retained as an expert witness,
including but not limited to all reports, deposition transcripts, trial transcripts and
engagement agreements.”
O:\ORDERS\07-219-CM-1.wpd -14-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 15 of 26
overly broad subpoena to bury him in this type of irrelevant “busy work.”
Merial argues that discovery of experts is not nearly as limited as Dr. Rowland claims.
In this regard, Merial cites Moses v. Halstead, in which another member of this court
explained:
The text of Rule 26(a)(2)(B) provides for the mandatory
disclosure of certain expert witness information, even without
a request from the opposing party. However, there is no
indication on the face of the rule to suggest that a party is
absolutely prohibited from seeking any additional information
about an opponent’s expert witnesses. In fact, Rule 26(b)(1)
describes the scope of allowable discovery as follows: “Parties
may obtain discovery regarding any matter, not privileged, that
is relevant to the claim or defense of any party.” In addition to
the text of Rule 26, the Court finds it to be significant that the
Advisory Committee, which created the mandatory disclosure
requirement in Rule 26(a)(2)(B), explicitly states that
[t]he enumeration in Rule 26(a) of items to be
disclosed does not prevent a court from requiring
by order or local rule that the parties disclose
additional information without a discovery
request. Nor are parties precluded from using
traditional discovery methods to obtain further
information regarding these matters, as for
example asking an expert during a deposition
about testimony given in other litigation beyond
the four-year period specified in Rule 26(a)(2)(B).
Western Resources thus stands for the proposition that requests
for documents are not objectionable merely because they seek
documents outside the scope of the expert disclosures required
by Rule 26(a)(2)(B).15
15
236 F.R.D. 667" date_filed="2006-07-28" court="D. Kan." case_name="Moses v. Halstead">236 F.R.D. 667, 677 (D. Kan. 2006) (Waxse, M.J.) (citations omitted) (quoting W.
Res., Inc. v. Union Pac. R.R., No. 00-2043, 2002 WL 1822428, at *4 (D. Kan. July 23,
2002)).
O:\ORDERS\07-219-CM-1.wpd -15-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 16 of 26
In light of cases like Moses v. Halstead, Merial is correct that expert discovery is not
as limited as Dr. Rowland suggests. However, Moses v. Halstead also suggests that Merial’s
document request is over broad on its face, not only in a temporal sense but also because of
its open-ended use of language such as “reflect, refer or relate” and “including but not limited
to.”16 That is, this sort of document request, as a practical matter, is nearly impossible to
interpret and police in terms of actual compliance. Therefore, Dr. Rowland need only
produce, for the ten-year period preceding the service date of the subpoena, for all cases in
which he was retained as an expert witness, the final versions of reports, deposition
transcripts, trial transcripts, and engagement agreements in his possession, custody, or
control. To this limited extent, Merial’s motion is granted.
5) Documents relating to the trials (research) Dr. Rowland has conducted on
Intervet’s PCV-2 vaccine.17 Merial argues that Dr. Rowland testified that he has directed
field trials for Intervet’s PCV-2 vaccine with one of his colleagues, Dr. Dick Hesse. Merial
further argues that Dr. Hesse developed Intervet’s PCV-2 vaccine, in particular, the product
that infringes Merial’s ‘601 patent. Merial asserts that documents relating to Dr. Rowland
and Dr. Hesse’s field trials of Intervet’s PCV-2 vaccine, or any other documents relating to
16
Id. at 672.
17
Request No. 4 in the subpoena served on Dr. Rowland seeks “[a]ll documents
reflecting, referring, or relating to any communications with others regarding or relating to
any of (1) the subject matter of your Declaration; (2) any of the opinions expresses in your
Declaration; (3) the ‘601 patent; (4) the Intervet v. Merial litigation; (5) the Merial v. Intervet
litigation; (6) the Intervet PCV-2 vaccine; and/or (7) the ‘594 patent, including, but not
limited to, any such communications with Intervet, Kenyon, or any experts or consultants for
Intervet or Kenyon, including, but not limited to, Dr. Fernando A. Osorio, M.V., Ph. D.”
O:\ORDERS\07-219-CM-1.wpd -16-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 17 of 26
Intervet’s PCV-2 vaccine, are relevant to this case (including but not limited to the
infringement issues, and Dr. Rowland’s bias as an expert for Intervet), but Dr. Rowland did
not produce any of these documents.
Dr. Rowland’s position seems to be that all of the documents have been produced by
K-State. But in its reply brief (doc. 36 at 16), and during the August 23, 2007 hearing,
Merial argued that Dr. Rowland may have other documents beyond those that were produced
by K-State and that he should be ordered to produce those materials. The court agrees with
Merial. Quite mindful that undoubtedly there will be some overlap or duplication involved,
Dr. Rowland shall produce all such documents in his possession, custody, or control that are
reasonably responsive to this request. In this regard, Merial’s motion is granted.
6) All relevant e-mails and attachments. Merial argues that Dr. Rowland
should be compelled to search for and produce all documents, and in particular e-mails, that
are responsive to each of the requests in the subpoena. Dr. Rowland objects on the basis that
this request is over broad, in that it would require him to search all of his papers and
electronic documents for any documents “relating” to any of the terms “PCV, PCV-1, PCV-
2, vectors, Open Reading Frames or epitopes.” The court agrees and therefore sustains Dr.
Rowland’s objection. In this respect, Merial’s motion is denied.
7) Drafts of Dr. Rowland’s declaration.18 Merial argues that Dr. Rowland is
18
Request No. 1 in the subpoena served on Dr. Rowland seeks “[a]ll non-identical
drafts of your Declaration, including, but not limited to, all handwritten or typed drafts of
your Declaration, and including any outlines of your Declaration and any notes related to
your Declaration prepared or taken in advance of or during the preparation of your
Declaration.”
O:\ORDERS\07-219-CM-1.wpd -17-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 18 of 26
obligated to produce the laptop computers and “pen drive”19 on which drafts of his
declaration were prepared. Merial further argues Dr. Rowland and Intervet’s lawyers should
be sanctioned for their “scheme” to avoid producing drafts of Dr. Rowland’s declaration.
Merial requests that, as a sanction for their inappropriate conduct, the court should require
Dr. Rowland and Intervet’s lawyers to compensate Merial for the costs involved in having
the “pen drive” and laptop computer hard-drives forensically analyzed to determine if any
drafts of the declaration can be recovered.
Dr. Rowland argues that: (1) prior to his deposition, Merial never sought discovery
of drafts of expert reports; and (2) no drafts of Dr. Rowland’s declaration exist, and thus
cannot be produced. Dr. Rowland also argues Merial’s request that Intervet’s attorneys turn
over the hard drives from their laptops and the pen drive used in the drafting of the Rowland
Declaration for “forensic analysis” should be rejected as it has nothing to do with
Dr. Rowland, has no place before this court other than for inflammatory effect, and that this
is the exact type of situation that Fed. R. Civ. P. 45(c)(3)(A) protects against.
The relevant time-line of events is best derived from two sources. The first is Dr.
Rowland’s own deposition testimony (as cited by Merial). The second is a supplemental
declaration of William G. James, II, a partner at Kenyon & Kenyon, LLP (“Kenyon”), the
law firm that represents both Intervet and Dr. Rowland (doc. 49).
On August 11, 2006, Merial served a request for production on Intervet pursuant to
19
A pen drive simply is a small device which plugs into laptop computer. It can store
very large amounts of data. The device is also sometimes called a USB flash drive, thumb
drive, pocket drive, or jump drive.
O:\ORDERS\07-219-CM-1.wpd -18-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 19 of 26
Fed. R. Civ. P. 34 requesting: “[a]ll documents prepared in connection with this civil action
by each person whom Intervet may call as an expert witness at the trial of this civil action.”
This request was No. 52 among 84. While Merial argues this request is broad enough to
cover drafts of experts’ reports, the fact remains that the request does not specifically
mention such drafts.
In a March 28, 2007 letter to Intervet’s lawyers, Merial stated, in pertinent part:
“Merial has considered Intervet’s suggestion that the parties will not be required to retain or
produce drafts of expert(s)’ reports and cannot agree to it.” Significantly, though, during the
August 23, 2007 hearing, it was acknowledged that Merial and Intervet never reached an
explicit and specific agreement that drafts of their experts’ reports would be preserved.
Dr. Rowland arrived at Kenyon’s Washington, D.C. offices on April 30, 2007, staying
through May 2, 2007, to finalize his declaration. Prior to his arrival, an electronic document
had been put together by Cedric Tan, an associate in the Kenyon firm. The electronic
document was prepared and stored on a portable USB memory device connected to a laptop
computer. Dr. Rowland testified that it was possible this draft declaration already contained
the claim constructions that Intervet was proposing, thus reflecting the constructions that
Intervet wanted Dr. Rowland to espouse as his own. Mr. James claims the document
included the background and experience of Dr. Rowland, a description of the ‘601 patent,
and the constructions of the ‘601 patent claim terms that had been developed by Dr. Rowland
and the Kenyon attorneys during their discussions the preceding months.
O:\ORDERS\07-219-CM-1.wpd -19-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 20 of 26
Over the course of April 30 to May 2, 2007, Dr. Rowland worked on the electronic
document at various times with Messrs. James and Tan and Ms. Patrice Jean, also an
associate with the Kenyon firm. Dr. Rowland saved all of his revisions and edits to the
documents on the pen drive. All revisions were saved over the original file, and no different
versions were saved on the pen drive. Mr. James claims that during the time he worked with
Dr. Rowland on May 2, 2007, Dr. Rowland had the pen drive plugged into his personal
laptop and he personally entered and saved all of the edits in the document on the pen drive.
It was Mr. James’ understanding that during the time that Mr. Tan and Ms. Jean were
working with Dr. Rowland, most changes to the electronic document were entered by Dr.
Rowland using his laptop, although some changes may have been input by Kenyon attorneys.
Mr. James states that during this time the pen drive was only plugged into Kenyon laptops
and Dr. Rowland’s personal laptop. He claims the document was not printed out until just
prior to its submission to the court in the D.C. Action. Mr. James states that he has been
informed by Kenyon’s information technology (“IT”) department that Kenyon’s computer
system does not audit print jobs and therefore does not have the ability to identify or recover
documents, such as Dr. Rowland’s declaration.
Mr. James states that after the declaration was completed and filed, the pen drive in
question was still connected to the Kenyon laptop in one of the Kenyon conference rooms.
Mr. Rowland has provided, in detail, the steps he has taken to locate the pen drive. However,
the pen drive remains missing. Mr. James also states that he has had his IT department
search all the computers the pen drive could have been connected to for any version of the
O:\ORDERS\07-219-CM-1.wpd -20-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 21 of 26
documents. He states that one document was found on the hard drive of a single Kenyon
loaner laptop (i.e., not assigned to a particular attorney). The document is titled “Declaration
of R. Robert Rowland Ph.D.” He claims the document is different from the Rowland
Declaration that was ultimately filed in the D.C. Action. Mr. James states that he does not
believe this particular document was the original document shown to Dr. Rowland on April
30, 2007, or that this particular document was ever shown to Dr. Rowland.
Merial argues that although Dr. Rowland and Intervet’s lawyers have successfully
destroyed many relevant drafts of the declaration, some prior draft information still may be
on the pen drive itself, and that the cache memory of the computers that Dr. Rowland used
may still have some or all of the drafts. If such drafts have not been written over, Merial
believes that forensic specialists may be able to recover them.
As evidenced by the parties’ briefs, courts have taken various positions with regard
to whether an expert must retain and produce drafts of his/her report. In Trigon Insurance
Co. v. United States,20 cited by Merial, the court cited various other cases that have held that
drafts of experts’ reports are discoverable. “Courts have even extended the scope of the rule
[Fed. R. Civ. P. 26(a)(2)(B)] to allow disclosure of ‘drafts of reports or memoranda experts
have generated as they develop the opinions they will present at trial.’”21 The court in Trigon
20
204 F.R.D. 277" date_filed="2001-11-09" court="E.D. Va." case_name="Trigon Insurance v. United States">204 F.R.D. 277 (E.D. Va. 2001).
21
Id. at 283 (citing B.C.F. Oil v. Consol. Edison Co. Of N.Y., Inc., 171 F.R.D. 57" date_filed="1997-01-29" court="S.D.N.Y." case_name="B.C.F. Oil Refining, Inc. v. Consolidated Edison Co. of New York, Inc.">171 F.R.D. 57, 62
(S.D. N.Y. 1997) (quoting Hewlett-Packard Co. v. Bausch & Lomb, Inc., 116 F.R.D. 533" date_filed="1987-07-17" court="N.D. Cal." case_name="Hewlett-Packard Co. v. Bausch & Lomb, Inc.">116 F.R.D. 533,
536 (N.D. Cal. 1987)); W.R. Grace & Co. v. Zotos Int’l, No. 89-CV-838S(F), 2000 WL
1843258, at *10 (W.D. N.Y. 2000) (“Courts have held that drafts of reports prepared by
testifying experts are subject to disclosure pursuant to Fed. R. Civ. P. 26(a)(2)(B).”)).
O:\ORDERS\07-219-CM-1.wpd -21-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 22 of 26
opined that “[g]iven that drafts may be used for cross-examination and other purposes, and
are not protected by another doctrine of privilege, drafts should be disclosed where, as here,
they are not solely the product of the expert[’s] own thoughts and work.” 22
On the other hand, Dr. Rowland argues that University of Pittsburgh v. Townsend,23
is directly on point on this issue. In Townsend, the University of Pittsburgh (the
“University”) sued several parties who allegedly subverted and misappropriated the
University’s rights and interest in valuable medical scanning technology. Defendants served
a request for production on the University seeking “all documents provided to or by . . . [the
University], revised by, relied upon, or otherwise used in consultation with or as a basis for
consultation with, any expert witness identified” by the University pursuant to Fed. R. Civ.
P. 26(a)(2). The University objected that the request was premature and stated that
responsive documents would be produced in accordance with Rule 26(a)(2) and the Case
Management Order. Defendants subsequently issued two subpoenas to two of the
University’s experts requesting they appear for depositions and produce all documents
reviewed or relied on in preparing the expert reports required by Rule 26(a)(2)(B). The
requests specifically included all drafts of the reports. At their depositions, the experts
testified that they did not retain previous drafts of their reports. The University’s counsel
added that it was their practice to instruct experts not to retain drafts.
22
Id.
23
No. 3:04-cv-291, 2007 WL 1002317 (E.D. Tenn. Mar. 30, 2007).
O:\ORDERS\07-219-CM-1.wpd -22-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 23 of 26
Defendants argued that, under Rule 26(a)(2), experts have an affirmative duty to
preserve draft reports. They argued that because discoverable evidence was destroyed, the
experts should be precluded from testifying at trial. The University countered that, until
defendants served the subpoenas shortly before the experts’ depositions, there were no
requests for production of drafts. Once the subpoenas were served, no drafts were destroyed.
The court in Townsend held that, contrary to defendants’ assertion, Rule 26(a)(2) does
not create an affirmative duty on the part of experts to preserve draft reports. The court also
found that defendants’ prior Rule 34 request for production of “all documents provided to
. . ., revised by, relied upon, or otherwise used in consultation with or as a basis for
consultation with, any expert witness” was “far from the model of clarity.” The subpoenas
served by defendants on the University’s experts included clear requests for draft reports.
Only at that point, the court said, did they have a duty to retain drafts and produce them at
their depositions. Earlier destruction of drafts was not a basis for excluding the experts’
testimony.24
Similarly, in the case at bar, it is unclear as to whether Dr. Rowland really was under
a legal obligation to produce all of the drafts of his declaration, especially since the Rule 34
request served by Merial on Intevet did not specifically seek drafts, and the fact that the
subpoena specifically seeking any drafts of the declaration was not served on Dr. Rowland
until after he had completed the declaration.
24
Id. at *4.
O:\ORDERS\07-219-CM-1.wpd -23-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 24 of 26
Based on the record presented, the court is unable to find that the process in which
Intervet, through its counsel and Dr. Rowland, prepared the declaration was an “intentional
scheme” meant to destroy discoverable evidence. In fact, during the hearing on August 23,
2007, the court inquired how Merial worked with its retained claim construction expert
witness. Mr. Kowalski, one of Merial’s lawyers, stated that he and Mr. Elsevier, another one
of Merial’s lawyers, sat down with their expert witness, Dr. Christopher Chase, with a lap
top computer that was “brand spanking new, nothing on it.” With one of Merial’s lawyers
supposedly only serving as a “scribe,” the declaration was written, edited, and finalized in
a single day, with the “save” key never being hit. Merial stated that the last thing they did
at the end of the day was save the document to a CD that has been preserved in a locked
drawer. Merial also claimed that the computer has been preserved should Intervet seek
production of its hard drive for a forensic analysis. Significantly, however, even if Intervet
and this court were to suspend their credulity about the limited involvement of Merial’s
counsel, it is uncontroverted that a forensic analysis of the hard drive would not provide any
information about whether a particular addition or deletion to the documents was suggested
by the expert or one of the lawyers involved in the process. Therefore, the court is
unpersuaded that what Merial has accused Intervet of doing is materially different than the
way in which Merial acted.
In any event, given the representations by Mr. James, the court cannot order
production of the pen drive as it apparently does not exist. It does appear, however, there is
a possibility that prior versions or drafts of Dr. Rowland’s declaration still may be available
O:\ORDERS\07-219-CM-1.wpd -24-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 25 of 26
to some extent on Dr. Rowland’s laptop computer, i.e., because the above-described pen
drive at times was plugged into that computer. During the August 23, 2007 hearing, the
court requested the parties work out some protocol for production of the material in issue.
Indeed, the court made some specific, practical suggestions in this regard, which
unfortunately but predictably have gone unheeded. Upon reflection, given the unique facts
presented here, the court has decided that Dr. Rowland will not be required to produce his
laptop computer for a forensic analysis as requested by Merial.
B. Miscellaneous Issues
In addition to disputes over the above-described categories of documents, the instant
motion presents a few other issues, as follows:
1) Confidentiality. Merial claims that during Dr. Rowland’s deposition he
refused to produce certain of the above-referenced categories of documents due to
confidentiality concerns. Merial argues this objection lacks merit because a protective order
has been filed in the D.C. Action. The court agrees.
2) Continuation of Dr. Rowland’s Deposition. Dr. Rowland argued that he should
not be required to appear for a second deposition. The court respectfully disagrees. Dr.
Rowland shall appear for a follow-up deposition limited to four hours and the scope of the
inquiry shall be limited to only the supplemental materials ordered produced in this order.
IV. Order
In consideration of the foregoing,
IT IS HEREBY ORDERED that, without prejudice to Merial’s right to file a motion
O:\ORDERS\07-219-CM-1.wpd -25-
Case 2:07-mc-00219-CM Document 52 Filed 08/30/07 Page 26 of 26
in the D.C. Action to disregard or exclude some or all of Dr. Rowland’s testimony, Merial’s
motion to compel in this court (doc. 1) is granted in part and denied in part. Dr. Rowland
shall produce all of the documents called for by this order by September 10, 2007. On a
date and time convenient to Dr. Rowland and counsel of record in the D.C. Action for Merial
and Intervet, Dr. Rowland shall be produced to Merial for another deposition by September
24, 2007.
Dated this 30th day of August, 2007, at Kansas City, Kansas.
s/James P. O’Hara
James P. O’Hara
U.S. Magistrate Judge
O:\ORDERS\07-219-CM-1.wpd -26-